CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(7.30) per share which missed the analyst consensus estimate of $(5.37) by 35.94 percent. This is a 61.44 percent increase over losses of $(18.93) per share from the same period last year.